Allspring Global Investments Holdings LLC Invests $8.93 Million in Phibro Animal Health Corporation $PAHC

Allspring Global Investments Holdings LLC bought a new stake in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 218,894 shares of the company’s stock, valued at approximately $8,931,000. Allspring Global Investments Holdings LLC owned 0.54% of Phibro Animal Health as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Financial Management Professionals Inc. bought a new stake in shares of Phibro Animal Health during the 2nd quarter valued at about $32,000. EverSource Wealth Advisors LLC lifted its holdings in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Phibro Animal Health by 768.2% in the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after buying an additional 4,079 shares during the period. State of Wyoming boosted its position in Phibro Animal Health by 148.8% during the 2nd quarter. State of Wyoming now owns 6,608 shares of the company’s stock valued at $169,000 after acquiring an additional 3,952 shares in the last quarter. Finally, Yousif Capital Management LLC purchased a new position in shares of Phibro Animal Health during the 2nd quarter worth approximately $200,000. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Price Performance

Shares of PAHC opened at $39.54 on Wednesday. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $46.42. The company has a market capitalization of $1.60 billion, a P/E ratio of 23.82, a price-to-earnings-growth ratio of 1.09 and a beta of 0.79. The firm has a 50 day moving average of $40.96 and a 200 day moving average of $36.35. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. The firm had revenue of $363.89 million during the quarter, compared to analysts’ expectations of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is 28.92%.

Insider Activity at Phibro Animal Health

In related news, CEO Jack Bendheim sold 5,752 shares of Phibro Animal Health stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36. Following the transaction, the chief executive officer directly owned 39,200 shares in the company, valued at approximately $1,604,456. The trade was a 12.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 146,554 shares of company stock valued at $6,338,444 over the last three months. Insiders own 50.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on PAHC shares. Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $31.40.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.